Neochord
Minneapolis, Minnesota, United States · Biotechnology, Health Care, Manufacturing · 20 employees
NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation. The company is dedicated to advancing the treatment of mitral regurgitation and developing innovative therapies for degenerative mitral valve disease.
Funding history
- Series seed — $493K — Mar 2025
- Series seed — $914K — Aug 2024
- Series seed — $4.6M — Jul 2023
- Series seed — $2.9M — Nov 2022
- Series seed — $2.9M — Sep 2022
Recent signals
- Mar 13, 2025: Raised $493K in Series seed
- Aug 29, 2024: Raised $914K in Series seed
- Feb 29, 2024: NeoChord Appoints Todd Berg as Chief Executive Officer
- Feb 22, 2024: NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
- Jul 05, 2023: Raised $4.6M in Series seed
- Nov 14, 2022: Raised $2.9M in Series seed
- Sep 22, 2022: Raised $2.9M in Series seed
- Mar 08, 2022: Raised $1.8M in Series seed
See plans & pricing → Track Neochord’s funding, hiring, and signals — with verified contacts — on Fundz.